Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug;84(5):779-804.
doi: 10.1002/ddr.22063. Epub 2023 Apr 21.

Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update

Gautam Kumar  1 , Amrutha C  1
Affiliations
Review

Natural products and their analogues acting against Mycobacterium tuberculosis: A recent update

Gautam Kumar et al. Drug Dev Res. 2023 Aug.

Abstract

Tuberculosis (TB) remains one of the deadliest infectious diseases caused by Mycobacterium tuberculosis (M.tb). It is responsible for significant causes of mortality and morbidity worldwide. M.tb possesses robust defense mechanisms against most antibiotic drugs and host responses due to their complex cell membranes with unique lipid molecules. Thus, the efficacy of existing front-line drugs is diminishing, and new and recurring cases of TB arising from multidrug-resistant M.tb are increasing. TB begs the scientific community to explore novel therapeutic avenues. A precise knowledge of the compounds with their mode of action could aid in developing new anti-TB agents that can kill latent and actively multiplying M.tb. This can help in the shortening of the anti-TB regimen and can improve the outcome of treatment strategies. Natural products have contributed several antibiotics for TB treatment. The sources of anti-TB drugs/inhibitors discussed in this work are target-based identification/cell-based and phenotypic screening from natural products. Some of the recently identified natural products derived leads have reached clinical stages of TB drug development, which include rifapentine, CPZEN-45, spectinamide-1599 and 1810. We believe these anti-TB agents could emerge as superior therapeutic compounds to treat TB over known Food and Drug Administration drugs.

Keywords: TB drug discovery; efflux pumps; multidrug-resistance; natural products; secondary metabolites; tuberculosis.

PubMed Disclaimer

References

REFERENCES

    1. Aggarwal, A., Parai, M. K., Shetty, N., Wallis, D., Woolhiser, L., Hastings, C., Dutta, N. K., Galaviz, S., Dhakal, R. C., Shrestha, R., Wakabayashi, S., Walpole, C., Matthews, D., Floyd, D., Scullion, P., Riley, J., Epemolu, O., Norval, S., Snavely, T., … Sacchettini, J. C. (2017). Development of a novel lead that targets M. tuberculosis polyketide synthase 13. Cell, 170(2), 249-259.
    1. Alfarisi, O., Alghamdi, W. A., Al-Shaer, M. H., Dooley, K. E., & Peloquin, C. A. (2017). Rifampin vs. rifapentine: What is the preferred rifamycin for tuberculosis? Expert Review of Clinical Pharmacology, 10(10), 1027-1036.
    1. AlMatar, M., Makky, E. A., Var, I., Kayar, B., & Köksal, F. (2018). Novel compounds targeting InhA for TB therapy. Pharmacological Reports, 70(2), 217-226.
    1. Altieri, A. S., & Kelman, Z. (2018). DNA sliding clamps as therapeutic targets. Frontiers in Molecular Biosciences, 5(NOV), 1-9.
    1. Amorim Franco, T. M., & Blanchard, J. S. (2017). Bacterial branched-chain amino acid biosynthesis: Structures, mechanisms, and drugability. Biochemistry, 56(44), 5849-5865.

MeSH terms

LinkOut - more resources